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NUMEROUS antigens have been des-
cribed to date that were claimed to cross-
react with the carcinoembryonic antigen
ofthe digestive tract (CEA) discovered by
Gold and Freedman (1965). Among them,
only one has been sufficiently purified
and characterized to allow further, more
detailed studies of its immunological
relationship with CEA, its identity with
other cross-reacting substances, and its
possible clinical value.
This antigen has been given 4 different
names. NCA (for " non-specific cross-
reacting antigen ") is our name for it
(von Kleist, Chavanel and Burtin, 1972)
and other names are NGP (for " normal
glycoprotein ") favoured by Mach and
Pusztaszeri (1972), CCA III by Newman
et al., (1972) and CE-X by Darcy, Turber-
ville and James (1973), who showed the
immunological identity of 3 of these
antigens (NCA, NGP and CE-X).
NCA is one of the 3 principal colonic
carcinoma antigens regularly present in
perchloric-acid extracts ofthese and other
tumours and normal tissues, and a ten-
acious contaminant of CEA preparations
(von Kleist et al., 1972; von Kleist, 1973).
There exist many physico-chemical simi-
larities between the two antigens; they
differfrom each other, however, in molecu-
lar weight and by the unshared antigenic
determinants on their respective mole-
cules. This permits their separation and
specific detection in tissues and body
fluids.
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NCA being closely related to CEA in
both reactivity and cellular distribution,
we wanted to know whether it might have
a similar oncological relevance to CEA.
Little is yet known (and even less pub-
lished) ofthe clinical value ofthis antigen,
especially inregard to cancer.
This study therefore tries to answer the
following questions:
What is the normal serum level of
NCA, and is it related to age, sex, or
blood group?
Do NCA levels rise in disease and, if
so, are there significant differences be-
tween levels in malignant and non-malig-
nant diseases?.
Lastly, are CEA and NCA serum
values correlated?
Controlsera
Fifty-one serum samples from pro-
fessional blood donors of both sexes
(M/F = 1.5) were obtained from the
Centre National de Transfusion Sanguine,
Paris. The age of the donors ranged from
23 to 56 years, 16% of the donors being
over 45, and 64% under 30. Nothing was
known to us about their clinical status
(except that they were hepatitis-free) and
smoking habits.
We shall therefore refer to this group
as " controls " rather than " normals ".
Patients' sera:
Sera from 185 patients were obtained
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TABLE I.-NCA Serum Levels in Non-cancerous Diseases
Diseased organ
Liver
Lung
Stomach and intestine
Pancreas
Skin, heart, uterus, spleen
Total No. ofsera
Diagnosis
Cirrhosis
Hepatitis
Bilial dyskinesia
Tuberculosis
Emphysema
Asthma
Bronchitis (acute & ch
Others
Crohn's disease
Diarrhoea & Sprue
Ulcers
Polyposis
Rectitis
Pancreatitis
Miscellaneous
No. ofcases
12
8
1
Total 21
13
7
3
ironic) 5
3
Total 31
2
6
4
3
4
6
Total 25
13
90
Serum levels (ng/ml)
A
<150 -260 -460 -660 >660
13 1 3 1 3
0 3 16 7 5
12 10
4 2
29 16
0
3
22
2
2
12
1
2
11
TABLE II.-NCA Serum Values in Cancerous Diseases
Site No. o:
Lung
Uterus, vagina, ovary
Colon 4
Stomach, pancreas I
Others (Tongue, thyroid, breast) I
Blood
Sera Total c
blood samples were from patients suffer-
ing from non-cancerous chronic and acute
diseases: 21 hepatic, 31 pulmonary, 25
gastrointestinal and 13 miscellaneous.
(Table I). The M/F ratio was 2 6, and
ages ranged from 19 to 87 years (28%
under 30 and 36% over 45). Ninety-five
sera were from patients with a diagnosed
carcinoma: 42 gastrointestinal, 13 gynae-
cological, 11 lung, and 19 at other sites,
(Table II). In this group, ages ranged
from 25 to 82 years, 6% being under 30
and 86% over 45.
All sera were tested simultaneously
and in duplicate for CEA and NCA; they
were kept deep-frozen (- 20°C) until
used.
Sixty additional serum samples from
Serum values (ng/ml)
fcases <150 -260 -460 -660 >660
11 2 0 6 2 1
13 2 7 2 2 0
42 10 22 4 2 4
13 2 5 3 3 0
11 2 3 2 4 0
5 2 2 0 0 1
95 20 39 17 13 6
colonic cancer patients, which we received
by courtesy ofProfessor E. Cooper, Leeds,
were tested in a horizontal study (follow-
up). They related to 12 different cases
followed for 3-9 months.
Immune sera
Immune sera were prepared in sheep
against purified NCA and CEA as already
described in detail (von Kleist et al., 1972;
Burtin and Chavanel, 1973). Antisera
against sheep gammaglobulins were either
of commercial origin (Eurobio, Paris) or
prepared byus in rabbits.
NCA and CEA were prepared following
established procedures (von Kleist et al.,
1972; Burtin and Chavanel, 1973). Both
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antigens have been compared with those
prepared by other groups (Troupel, 1974;
Darcy et al., 1973).
The radioimmunoassay was used in a
microversion, with a final volume of
400 ,ll. Labelling of the antigens with
1251 was done by the chloramine-T
method (Hunter and Greenwood, 1964).
Sera were tested directly, without PCA
extraction. The double-antibody tech-
nique adapted from Laurence et al. (1972)
was employed throughout. Sera (or anti-
gens) were preincubated with antisera for
36 h at 4°C, the labelled antigen was then
added and the mixture incubated for
another 24 h at 4°C. The separation of
the labelled complex was obtained by
adding a second antibody directed against
the first one. The precipitate was collec-
ted by centrifugation. The sensitivity of
the assay was considered adequate, since
4-6% inhibition was obtained with 0 4 ng
of CEA in 200 ,tl (2 ng/ml). This inhibi-
tion is obtained with 1-6 ng NCA/200 ,ul
(8 ng/ml).
ATormal serum levelfor NCA
Serum levels ranging from 30 to
510 ng/ml have been measured in the
controls, the mean being 130 ng/ml (s.e.
16.33). The dispersion being rather
high, we chose 150 ng/ml as cut-off point
(lowest mean value 118 ng/ml + 2 s.e.)
for the clinical study. According to
this limit, 350o (18/51) of blood donors
have an elevated NCA. This is compar-
able to that for CEA, (31% elevated:
> 4 ng/ml). Six sera had both high NCA
and high CEA. If one excludes these (as
being " abnormal "), the mean NCA
value falls to 118 ng/ml (see above)
though this is not significantly different
from 130 ng/ml.
Other sera had elevated levels of
either NCA or CEA, which suggested that
the two antigens were independent. This
has been confirmed statistically. The
serum values of CEA and NCA are not
strongly correlated, either in this group
or in the other two groups. The correla-
tion coefficientintheblood-donorgroupwas
0 77, and for the two other groups 0-51
and 0-56 respectively. The chi-square
test showed no significant difference
between the sexes, blood groups, or with
age in any of the three groups.
Non-neoplastic diseases
The overall percentage of raised
(>150 ng/ml) NCA serum levels in this
group was 68% (61/90 cases), compared
to 60% for CEA.
It is known that NCA is very abundant
in pulmonary tissues, so we wanted to
test whether NCA serum levels were
abnormal in lung diseases, particularly
those associated with tissue destruction,
as in tuberculosis. Also, NCA being a
glycoprotein, wewereinterested in illnesses
known to affect serum glycoproteins, e.g.
liver diseases.
There was a striking difference between
the two organs: All 31 sera from patients
with pulmonary diseases showed clearly
raised NCA levels (>180 ng/ml) as com-
pared to 41% for CEA (>4 ng/ml). The
13 cases of tuberculosis all had values
above 340 ng/ml.
In contrast, in the benign liver dis-
ease group, none of the 8 hepatitis sera
showed elevated NCA levels: on the con-
trary, they were rather low (< 100 ng/ml).
In sera from the 12 cases of cirrhosis, 50%
showed levels raised above 350 ng/ml,
2/6 of which, however, had pulmonary
complications. The overall percentage of
raised NCA levels in benign liver diseases
was only 33%, as against 29% for CEA.
Intermediate NCA elevation is found
in sera from non-cancerous gastrointest-
inal diseases: 13/25 (52%) had values
over 150 ng/ml. If one looks at the 18
sera from cases of intestinal conditions
alone, 50% were raised (as compared to
67% for CEA), and 7/9 ofthese came from
patients with inflammatory diseases
(Table I). There were significantly higher
mean serum values in men than in women
(P = 0 002) for NCA, but not for CEA.
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FIG.. 1. Comparison of NCA serum levels in non-
cancerouis andt cancerous patients.
Carcinomas
It is now established that high serum
levels of CEA are practically always
associated with neoplastic disease, but
the same does not hold for NCA, which is
generally little raised in malignancy, and
410 of all carcinomas tested (39/95) had
their maximal serum levels only moder-
ately raised (150-260 ng/ml, Fig. 1).
That this is a typical range for tumours is
shown when the carcinomas analysed by
organ still follow this pattern. The most
interesting group in respect of NCA was
that of patients with lung tumours.
Contrary to expectation, these neoplasias
gave similar results to the non-cancerous
conditions, but only 9/11 sera showed
levels above 260 ng/ml. Thus there is no
distinction between NCA values in malig-
nant and non-malignant lung diseases.
Other carcinomas follow this pattern:
Moderately raised levels (> 150ngl!
ml) were found in 7/11 gynaecological
cancers, 27/52 gastrointestinal tumours,
(5/10 gastric and 22/42 colonic) and the
single hepatoma (Table II).
Sixty-eight of all 95 tumour sera had
raised CEA values, giving a mean value in
this group above that in the previous
one. For NCA, however, the mean is
lower than that of the benign diseases.
Comparison of the average values
obtained for both antigens in the 3 groups,
(non-cancerous and cancerous diseases,
and controls) shows that there are highly
significant differences only between the
controls and the 2 groups ofpatients. The
differences between cancerous and non-
cancerous diseases are insignificant. It is
evident that NCA measurements are of
no more use than those of CEA for diag-
nostic purposes (Table III).
In this cancer group, males had sig-
nificantly higher serum levels than females
(P 0-01), the chi-square test showing
that both sexes were homogeneous.
Follow- tp
AWre tested whether the poor correlation
between the initial CEA and NCA serum
levels would be confirmed in long-term
horizontal studies. The colonic cancers
confirmed that NCA and CEA varied
independently of each other and also
that NCA, though it rises, soon levels off
in the zone typical for carcinomas,
regardless of stage. Fig. 2 illustrates that,
irrespective of changes in CEA levels,
NCA concentration, though in the patho-
logical range, stays stable.
TABLE III.-NCA and CEA (ng/ml) in Patients' Sera
NCA CEA
Diagnosis No Mlean s.e. Mean s.e. Age (years) <
Blood doonors 51 130 16 5 1 23-56
Non-cancerous diseases 90 312 25 2:3 19-88
Carciniomas 95 298 24 46 1(1 25 -82
236
104
<30 0°/O
65
28
6
>45 0
16
36
86
878
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NCA
CEA
1 2 3 4 k 2 3 4 ~~5 6 7 8
months
FIG. 2.-Follow-up of 2 colonic carcinoma
patients.,(a and b) by CEA and NCA serum
measurements (logscale).
Discussion
The present study shows that NCA is
of less clinical value than CEA. NCA is
not specific for any malignant diseases,
to justify its inclusion in the current
assemblage of diagnostic aids. NCA has
40-50-fold higher serum concentrations
than CEA in controls. Its serum level is
more easily raised in benign conditions
than is that ofCEA. Therise is spectacular
in pulmonary diseases, including such
common conditions as chronic bronchitis.
This may explain some of the high serum
levels in our blood donor controls. Benign
hepatic disorders have near-normal NCA
levels, indicating that these are not altered
by illnesses known to disturb serum glyco-
protein levels.
To date, no circulating antigen is
known to serve as a diagnostic test of
neoplasia. However, whilst very high
serum CEA levels are exceptionally found
in some non-cancerous diseases, they are
indicative of malignancy. For NCA it
seems the other way round: NCA is only
moderately raised in cancer.
Two possible causes for the high levels
in benign pulmonary disease are:
(1) Tissue destruction with liberation
of antigen. This would apply more to
tumours and tuberculosis than to chronic
bronchitis.
(2) Inflammation, with consequent
death of white cell elements such as
granulocytes, in which NCA has been
described as a cytoplasmic component
(Burtin, Quan and von Kleist, 1975). This
explanation seems the more probable
at present because, unlike carcinomas,
tuberculosis and bronchitis are regularly
accompanied by inflammatory cell infiltra-
tion. Also, 7/9 benign intestinal diseases
with raised NCA levels were inflammatory
in nature. Ifthis hypothesis were proved
true (i.e. that NCA was regularly raised
in inflammatory diseases), the NCA test
might interest clinicians other than oncol-
ogists. The only evidence ofgene regula-
tion ofeither antigen is a report by Lynch
and Guirgis (1973), who saw high CEA
serum levels more frequently in families
with the so-called cancer family syndrome.
We saw in our tumour group higher CEA
serum levels in men than women (as has
been seen for NCA in the non-cancerous
group). This may be due to the limited
number investigated.
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